Czechia· CZ-0168342

BETAFERON

A interferon beta-1b product containing interferon beta-1b, registered in Czechia by Bayer AG, Leverkusen. The same ATC class is registered in 14 of our 19 countries.

ATC L03AB08

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedBETAFERONATCL03AB08REGISTER NO.CZ-0168342PACKS LISTED0CHECKEDSeptember 28, 2026

Where it is registered

Interferon beta-1b is registered in 14 of 19 countries.

Countries holding a registration under ATC L03AB08 (interferon beta-1b), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 9 of them publish a price we can compare per daily dose

Interferon beta-1b · ATC L03AB08

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

SÚKL (Czech Republic)
Active substance
INTERFERON BETA-1B
Manufacturer
Bayer AG, Leverkusen
Country
Czechia (CZ)
ATC code
L03AB08
ATC class
Interferon beta-1b
Defined daily dose
4 MIO, E
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

347 interactions on record for interferon beta-1b.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Interferon beta-1b · interactions on record

347 records

  • 15 severe
  • 332 moderate

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • ZidovudineJ05AF01severe
  • ClotrimazoleA01AB18moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Interferon beta-1b in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All interferon beta-1b products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Betaferon
  • Liechtenstein · Betaferon
  • Norway · Betaferon

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b6f60645-4f9d-45ec-a2aa-edb78b742c0e
GET /v1/drugs/b6f60645-4f9d-45ec-a2aa-edb78b742c0e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "INJ PSO LQF",
  "source": "sukl",
  "strength": "250MCG/ML",
  "pack_size": "2X14+2X14X1,2ML ISP+AD",
  "substance": "INTERFERON BETA-1B",
  "cz_kod_sukl": "0168342",
  "product_type": "BT",
  "substance_codes": "14276",
  "registration_state": "R",
  "registration_number": "EU/1/95/003/012"
}

See everything about interferon beta-1b.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.